0 rating

Noninvasive Imaging in the Evaluation 
of Pulmonary Hypertension

Asghar A Fakhri, MD1, Vikas K Rathi, MD, FACC2, Rachel Hughes-Doichev, MD, FASE1, and Raymond L Benza, MD1

Evaluation of pulmonary artery (PA) hemodynamics, right ventricular (RV) structure, and RV function is crucial in the management of pulmonary hypertension (PH), whether due to left-sided heart failure (LHF), chronic thromboembolic disease, pulmonary parenchymal disease, pulmonary arterial hypertension (PAH), congenital heart disease (CHD), or pathology extrinsic to the PAs [1,2]. Noninvasive cardiac imaging modalities that are currently used to evaluate PH include echocardiography, radionuclide imaging, computed tomography (CT), and cardiovascular magnetic resonance imaging (CMR). Here, we will discuss the utility and merits of each modality, outline comparisons with invasive hemodynamic measurements and clinical outcomes, and summarize the limitations of each modality.

  • Table 1
outlines the utility of each modality. It should be noted that although many of these imaging parameters, especially for echocardiography and CMR, have been evaluated for diagnostic purposes, their role in monitoring response to therapy is less well studied using prospective analyses and requires further validation.

Return to top


Diagnostic Criteria For Dynamic Contrast-Enhanced Magnetic Resonance Imaging Of The Breast
Botond K Szabó and Maria Kristoffersen Wiberg
CML Breast Cancer
Pharmacotherapeutic Options for Pulmonary Arterial Hypertension
Myung H Park, MD
CML Pulmonary Hypertension
Congenital Heart Disease and Pulmonary Arterial Hypertension: Focus on Eisenmenger’s Syndrome
Julie Wacker and Maurice Beghetti, MD
CML Pulmonary Hypertension
Endothelial Progenitor Cells as a Target for Therapy of Pulmonary Hypertension
Laszlo Farkas, MD1,2,3, and Martin R Kolb, MD, PhD1,2
CML Pulmonary Hypertension
Inflammatory Mechanisms 
in Pulmonary Hypertension
Ali Sadoughi, MD1,2, Yinzhong Zhang MD, PhD1, Edmund J Miller, PhD, FRSC1,3,4, and Arunabh Talwar, MD, FCC P1,2,3,4
CML Pulmonary Hypertension